FGF21 GLP1 Double Gene-Modified Mesenchymal Stem Cell Patent Application for Metabolic Disease Treatment
Summary
The USPTO published patent application US20260108558A1, filed August 21, 2025, covering a modified mesenchymal stem cell engineered to co-express FGF21 and GLP-1 proteins, intended for treating metabolic diseases. The application names inventors Haifeng DUAN, Binghua XUE, Jing XIE, and Zhenli ZHANG, and specifies CPC classifications including A61K 35/28, A61P 3/10, C07K 14/50, C07K 14/605, and various C12N cellular-therapy classifications. Publication of this application creates prior art that may affect freedom-to-operate analyses for parties developing related cellular-therapy approaches for metabolic disease.
“The mesenchymal stem cell is capable of expressing: (1) a first protein, which is selected from FGF21 or a variant thereof, or a first fusion protein comprising the FGF21 or the variant thereof; and (2) a second protein, which is selected from GLP-1 or a variant thereof or a second fusion protein comprising the GLP-1 or the variant thereof.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 203 changes logged to date.
What changed
The USPTO published patent application US20260108558A1 for a modified mesenchymal stem cell expressing FGF21 and GLP-1 fusion proteins, filed August 21, 2025. The application discloses pharmaceutical compositions comprising the modified cell or its culture supernatant for treating metabolic diseases.
Competitors developing cellular-therapy approaches for metabolic disease should monitor this application's examination progress. While the application remains pending, publication establishes prior art that could affect freedom-to-operate for similar technologies. Parties pursuing related stem-cell or gene-therapy programs may wish to conduct landscape reviews to assess potential overlap with the disclosed FGF21/GLP-1 co-expression strategy.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
FGF21 AND GLP1 DOUBLE GENE-MODIFIED MESENCHYMAL STEM CELL AND USE IN TREATING A METABOLIC DISEASE
Application US20260108558A1 Kind: A1 Apr 23, 2026
Inventors
Haifeng DUAN, Binghua XUE, Jing XIE, Zhenli ZHANG
Abstract
Provided are a modified mesenchymal stem cell and culture supernatant thereof, and a pharmaceutical composition comprising said cell or culture supernatant thereof. The mesenchymal stem cell is capable of expressing: (1) a first protein, which is selected from FGF21 or a variant thereof, or a first fusion protein comprising the FGF21 or the variant thereof; and (2) a second protein, which is selected from GLP-1 or a variant thereof or a second fusion protein comprising the GLP-1 or the variant thereof. Also provided is the use of the modified mesenchymal stem cell and culture supernatant thereof, and the pharmaceutical composition comprising said cell or culture supernatant thereof in the treatment of metabolic diseases and in the preparation of a medicament for treating metabolic diseases.
CPC Classifications
A61K 35/28 A61P 3/10 C07K 14/50 C07K 14/605 C07K 2319/30 C12N 5/0662 C12N 5/0663 C12N 5/0665
Filing Date
2025-08-21
Application No.
19306678
Named provisions
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.